Kj. Henning et al., A NATIONAL SURVEY OF IMMUNIZATION PRACTICES FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, JAMA, the journal of the American Medical Association, 277(14), 1997, pp. 1148-1151
Objectives.-To describe the frequency and patterns of use of routine c
hildhood and hepatitis B, pneumococcal, influenza, and meningococcal v
accines following allogeneic bone marrow transplantation (BMT). Design
, Setting, and Participants.-Survey of all US transplantation centers
participating in the National Marrow Donor Program (NMDP) during 1994.
Main Outcome Measures.-Use, timing, and total doses of selected vacci
nes given to patients younger than 7 years and patients aged 7 years o
r older following allogeneic BMT. Results.-Of 66 centers associated wi
th the NMDP, 45 (68%) responded. A total of 97% of centers performing
transplants on patients younger than 7 years and 88% of centers perfor
ming transplants on patients aged 7 years or older gave either the dip
htheria-tetanus vaccine or the diphtheria-tetanus-pertussis vaccine co
mpared with 77% and 58% usage, respectively, of Haemophilus influenza
type b conjugate vaccine (P=.03 and .003, respectively). Centers were
more likely to administer inactivated poliovirus and measles-mumps-rub
ella vaccines to patients younger than 7 years than to the older age g
roup (94% vs 73% for poliovirus, P=.02; and 94% vs 70% for measles-mum
ps-rubella, P=.01). About one half of centers routinely administer hep
atitis B vaccine and approximately three quarters immunize with pneumo
coccal and influenza vaccines. Few programs, regardless of age of bone
marrow recipient, use multiple vaccine (greater than or equal to 2) d
oses. The number of schedules reported for specific vaccines varied wi
dely (3-11 schedules per vaccine). Conclusions.-Despite convincing evi
dence that patients lose protective antibodies to vaccine-preventable
diseases following allogeneic BMT and accumulating data showing the sa
fety and efficacy of many vaccines after BMT, vaccines are underutiliz
ed and schedules vary widely at US transplant centers. National guidel
ines for optimal doses and timing of vaccines after BMT are warranted.